<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="time course results demonstrated that IBV yields were reduced with" exact="treatment" post="at 0â€&quot;4â€‰h after infection, and the mechanistic research verified"/>
 <result pre="infection, and the mechanistic research verified that Lianhua-Qingwen capsule has" exact="hemagglutination" post="inhibition activity against B/Guangzhou/0215/2012 but not A/California/04/2009. In addition"/>
 <result pre="than those in controls. Further research confirmed that the combination" exact="treatment" post="of 200â€‰mg/kg/day of Lianhua-Qingwen capsule with 2â€‰mg/kg/day of oseltamivir"/>
 <result pre="of Lianhua-Qingwen capsule with 2â€‰mg/kg/day of oseltamivir significantly reduced IBV" exact="infection" post="over the individual administration of either alone in vivo."/>
 <result pre="viruses (IAVs) in annual seasonal epidemics. The proportion of IBV" exact="infection" post="cases out of total influenza-positive cases varies from approximately"/>
 <result pre="Antiviral drugs play an important role in the prevention and" exact="treatment" post="of IBV. The neuraminidase inhibitors (NAI) include oseltamivir, intravenously"/>
 <result pre="and Maxing Shigan Tang, which have been used historically for" exact="treatment" post="of influenza-like illness in China [13]. When a randomized,"/>
 <result pre="double-blind, positive-controlled clinical trial of LQ anti-influenza A (H1N1) virus" exact="treatment" post="was performed in China, the results confirmed that it"/>
 <result pre="as oseltamivir [14]. LQ was approved for clinical trials as" exact="treatment" post="for influenza infection by the FDA in 2016. In"/>
 <result pre="LQ was approved for clinical trials as treatment for influenza" exact="infection" post="by the FDA in 2016. In addition, our previous"/>
 <result pre="LQ in IBVs was tested by cytopathic effect (CPE). Three" exact="infection" post="models were constructed. Before infection, 106 TCID50 of virus"/>
 <result pre="Pre-C). LQ was used to treat cells at 2â€‰h after" exact="infection" post="(posttreatment of virus, Post-V). The supernatant was collected at"/>
 <result pre="infection, and the coverslips were prepared for use in the" exact="immunofluorescence" post="assay by washing twice. 2.7. Hemagglutination Inhibition Assay Then,"/>
 <result pre="concentrations of LQ was mixed with an equivalent of eight" exact="hemagglutination" post="units of virus solution. The plate was incubated at"/>
 <result pre="then 50â€‰Î¼L of 0.5% chicken erythrocyte suspension was added. The" exact="hemagglutination" post="inhibition activity of LQ was defined in complete inhibition"/>
 <result pre="of LQ was defined in complete inhibition of influenza virus" exact="hemagglutination" post="activity after incubation for 40â€‰min at room temperature. 2.8."/>
 <result pre="PBS three times. The viral binding was measured using an" exact="immunofluorescence" post="assay. 2.9. Immunofluorescence Assay The cells were fixed with"/>
 <result pre="solution without virus. The drugs were administered at 4â€‰h before" exact="infection" post="and continued for 5 days once per day, with"/>
 <result pre="with oseltamivir alone or combined with LQ from 4â€‰h before" exact="infection" post="to 4 days after infection with the day of"/>
 <result pre="with LQ from 4â€‰h before infection to 4 days after" exact="infection" post="with the day of infection defined as 0 day,"/>
 <result pre="infection to 4 days after infection with the day of" exact="infection" post="defined as 0 day, and equivalent amounts of PBS"/>
 <result pre="Early Phase of Influenza B Virus Replication According to three" exact="treatment" post="models representing prevention (pretreatment of cells, Pre-C), direct action"/>
 <result pre="results (Figure 1(b)) showed that IBV yield was reduced with" exact="treatment" post="with 0.6â€‰mg/mL of LQ at 0â€&quot;4â€‰h after infection, but"/>
 <result pre="treatment with 0.6â€‰mg/mL of LQ at 0â€&quot;4â€‰h after infection, but" exact="treatment" post="was not effective in reducing yield at more than"/>
 <result pre="with 0.6â€‰mg/mL of LQ for 8â€‰h. Compared to nontreatment or" exact="treatment" post="with the same concentration of medicine solvent (0.12% DMSO),"/>
 <result pre="against B/Guangzhou/0215/2012 but not A/California/04/2009. To confirm this result, indirect" exact="immunofluorescence" post="microscopy of viral binding was performed, and there was"/>
 <result pre="IFN-Î»1 (113-fold) in the A549 cells at 12â€‰h after IBV" exact="infection" post="compared to GAPDH gene. Also, a reduction of all"/>
 <result pre="Inflammation of Lungs in Mice Infection Model To verify the" exact="treatment" post="effect of LQ in vivo, the survival rate was"/>
 <result pre="mice showed severe interstitial pneumonia at 6 days after IBV" exact="infection" post="(Figure 5(b)). In the positive control, ribavirin treated mice"/>
 <result pre="the pathological changes in the lungs (Figure 7) showed that" exact="treatment" post="with oseltamivir at doses of 2 and 10â€‰mg/kg/day in"/>
 <result pre="course also indicated that IBV yield was reduced with LQ" exact="treatment" post="at 0â€&quot;4â€‰h after infection. It demonstrated that LQ may"/>
 <result pre="vRNP in nucleus. In this study, NP was localized by" exact="immunofluorescence" post="staining. The results showed potent inhibitory effect of LQ"/>
 <result pre="The results clarified that LQ plays a role in the" exact="hemagglutination" post="inhibition (HI) activity of influenza B virus (B/Guangzhou/0215/2012) but"/>
 <result pre="not influenza A virus (A/California/04/2009). To confirm this result, an" exact="immunofluorescence" post="assay for viral binding was performed, and the viral"/>
 <result pre="of B/Guangzhou/0215/2012 to the MDCK cells surface was reduced by" exact="treatment" post="with the LQ, but the same result did not"/>
 <result pre="in the future. The cytokines and chemokines evoked by the" exact="infection" post="have been shown to contribute to the pathology associated"/>
 <result pre="shown to contribute to the pathology associated with influenza virus" exact="infection" post="[22]. LQ is a combination of traditional Chinese medicines."/>
 <result pre="antiviral activity, it may also have anti-inflammatory activity. Influenza virus" exact="infection" post="causes cell necrosis/apoptosis, which induces an immune reaction and"/>
 <result pre="A virus, animal models for the study of influenza B" exact="infection" post="are lacking. This lack of studies is due to"/>
 <result pre="Organization201290427928810.2471/blt.11.09695822511824 4MoonJ.-H.NaJ.-Y.KimJ.-H.et al.Neurological and muscular manifestations associated with influenza B" exact="infection" post="in childrenPediatric Neurology20134929710110.1016/j.pediatrneurol.2013.04.00423859854 5ThabetF. I.KhalilS.NazF.DymeI. Z.Cerebellar mutism and reversible"/>
 <result pre="virus infection: efficacy and resistanceAntiviral Research2013100252053410.1016/j.antiviral.2013.08.02324013000 10SatoM.SaitoR.SatoI.et al.Effectiveness of oseltamivir" exact="treatment" post="among children with influenza A or B virus infections"/>
 <result pre="effectiveness of oseltamivir against influenza B contrasted with influenza A" exact="infection" post="in childrenClinical Infectious Diseases200744219720210.1086/50992517173216 12KawaiN.IkematsuH.IwakiN.et al.A comparison of the"/>
 <result pre="12KawaiN.IkematsuH.IwakiN.et al.A comparison of the effectiveness of oseltamivir for the" exact="treatment" post="of influenza A and influenza B: a Japanese multicenter"/>
 <result pre="and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the" exact="treatment" post="of influenza: a multicentre, double-blind, randomised phase 2 trialThe"/>
 <result pre="of N-acetylcysteine and ribavirin to protect from lethal influenza viral" exact="infection" post="in a mouse modelInternational Journal of Immunopathology and Pharmacology20041719910210.1177/03946320040170011415000873"/>
 <result pre="expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus" exact="infection" post="in BALB/c miceClinical and Vaccine Immunology201421457057910.1128/cvi.00816-1324521786 36HaasbachE.HartmayerC.PlanzO.Combination of MEK"/>
 <result pre="oseltamivir leads to synergistic antiviral effects after influenza A virus" exact="infection" post="in vitroAntiviral Research201398231932410.1016/j.antiviral.2013.03.00623523553 Figure 1 Influenza B virus yield"/>
 <result pre="in vitroAntiviral Research201398231932410.1016/j.antiviral.2013.03.00623523553 Figure 1 Influenza B virus yield after" exact="treatment" post="with LQ. (a) The effect of treatment with LQ"/>
 <result pre="virus yield after treatment with LQ. (a) The effect of" exact="treatment" post="with LQ against influenza B virus in different models:"/>
 <result pre="course assay: cells were treated with 0.6â€‰mg/mL of LQ after" exact="infection" post="with B0215 (MOIâ€‰=â€‰0.01); the supernatant was collected and titrated"/>
 <result pre="detected limitation. âˆ—P &amp;lt; 0.05, âˆ—âˆ—P &amp;lt; 0.01 compared to" exact="treatment" post="with 0.12% DMSO (the concentration of 0.6â€‰mg/mL of LQ)."/>
 <result pre="LQ (0.6â€‰mg/mL), or 0.12% DMSO. The cells were fixed and" exact="immunofluorescence" post="assay was performed at 8â€‰h after infection. Figure 2"/>
 <result pre="binding activity of influenza B virus B0215. (a) Influenza virus" exact="hemagglutination" post="inhibition assay after treatment with LQ. (b) Immunofluorescence assay"/>
 <result pre="B virus B0215. (a) Influenza virus hemagglutination inhibition assay after" exact="treatment" post="with LQ. (b) Immunofluorescence assay for influenza B virus"/>
 <result pre="influenza B virus and influenza A virus viral binding after" exact="treatment" post="with 0.6â€‰mg/mL of LQ or the same concentration of"/>
 <result pre="cytokine mRNA expression level in influenza B virus-infected A549â€‰cells after" exact="treatment" post="with Lianhua-Qingwen. âˆ—âˆ—âˆ—P &amp;lt; 0.001 compared to control via"/>
 <result pre="survival and viral titer in lungs of B0215â€�infected mice after" exact="treatment" post="with LQ. (a) Weight change after treatment. (b) Survival"/>
 <result pre="titer in lungs after treatment. The dotted line is limited" exact="detection" post="(LD). âˆ—P &amp;lt; 0.05 compared to placebo via t-test."/>
 <result pre="Figure 5 The pathological change of B0215â€�infected mice lungs after" exact="treatment" post="with LQ. (a) Uninfected. (b) Placebo. (c) Treated with"/>
 <result pre="infected mice lungs treated with LQ combined with oseltamivir after" exact="infection" post="with influenza B. (a) Uninfected. (b) Treated with 75â€‰mg/kg/day"/>
</results>
